Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...

GSK said its long-acting injectable HIV drug, Cabenuva, worked better than daily pills for some patients, according to interim results from a late-stage clinical trial. The therapy, developed by ...

GSK'227 targets B7-H3 ... Dovato up 27% and long-acting injectables, Cabenuva and Apretude, which reached £1.3 billion of sales and contributed more than 50% of total growth.

and a contribution by recently-launched long-acting injectable Cabenuva (cabotegravir). On the downside, GSK's COVID-19 therapy Xevudy (sotrovimab) saw a slump in demand, with sales falling to £ ...

GSK expects 2025 sales growth between 3% and ... HIV sales increased 13%, driven by strong demand for Cabenuva and Apretude, which reached £1.3 billion in 2024. Management flagged a £150 million ...

GSK managed to beat analysts’ revenue predictions for the first quarter of the year, despite an 8% decline in turnover pegged back by declines in COVID-19-related products. The group posted £6. ...

GSK saw turnover increase by 7 per cent to £31.7billion over the full year, thanks to rising demand for specialty medicines like HIV treatments Dovato and Cabenuva and sales of oncology medicines ...

GSK plc GSK reported fourth-quarter 2024 core ... J&J JNJ-partnered Juluca — and long-acting medications, Apretude and Cabenuva. The combined revenues from these four drugs contributed more ...